For Some Leukemia Patients Who Fail Induction Therapy, Chemotherapy Proves Life-Saving
The largest study ever of such pediatric ALL patients identified a subset of young children who achieved 10-year survival rates of 72 percent after additional chemotherapy rather than bone marrow transplantation. The patients are among the estimated 85 percent of children with ALL whose cancer begins in white blood cells destined to become B cells.
The results appear in the April 12 edition of the New England Journal of Medicine. The study involved researchers from 14 research groups in the U.S., Europe and Asia.
"Induction failure is a rare event, affecting just 2 to 3 percent of all pediatric ALL patients. But these children are at very high risk for a bad outcome and were always considered candidates for bone marrow transplantation," said Ching-Hon Pui, M.D., chair of the St. Jude Children's Research Hospital Department of Oncology. "These results tell us that induction failure should no longer be considered an automatic indication for a transplant." Pui is the study's corresponding author.
Improvements in both chemotherapy and transplantation prompted investigators to revisit the question of optimal care for these patients. But no single institution or nation had enough patients to answer it. "This study shows the importance of international collaboration to advance the treatment outcome for these patients," said first author Martin Schrappe, M.D., University Medical Center Schleswig-Holstein, Kiel, Germany.
Investigators evaluated the outcomes of 44,017 ALL patients age 17 and younger whose cancer was discovered during a 15-year period ending in December 2000. Each was treated on a clinical trial at one of the centers participating in this international collaborative analysis. St. Jude patients were part of the study. Researchers tracked 1,041 patients whose cancer did not go into remission following four to six weeks of induction therapy.
Historically, the prognosis has been grim for patients who fail induction therapy. While overall long-term survival for childhood ALL patients climbed to 80 percent during the 15 years covered in this study, it was just 32 percent for patients who did not enter remission after the first intense weeks of treatment. The definition of induction failure differed slightly among the clinical trials included in this analysis.
The study found long-term survival rates of 72 percent among some young patients with B-lineage ALL treated with additional chemotherapy following induction therapy failure. The patients were ages 1 through 5 when their cancer was found and many had more than 50 chromosomes in their leukemia cells, rather than the normal number of 46 chromosomes. Together they accounted for about 25 percent of patients whose disease did not go into remission following induction therapy.
The children who benefited from additional chemotherapy also had no other markers of high risk, including high white blood cell counts or chromosomal rearrangements involving the MLL gene.
The study found transplants remain the best hope for many other young ALL patients who fail induction therapy. The patients included those whose cancer originated in white blood cells known as T cells. T cell ALL accounts for 12 to 15 percent of childhood ALL, but about 38 percent of patients in this study. The transplants involve killing the patient's own diseased bone marrow and replacing it with blood-producing stem cells from a genetically matched donor. The procedure leaves patients at risk for a variety of immediate and chronic health problems.
Patients with a chromosomal rearrangement known as the Philadelphia chromosome were not included in the analysis because new drugs have led to a dramatic improvement in their outcome. About 13 percent of ALL induction treatment failures involved patients with the genetic alteration.
The other authors are Stephen Hunger, University of Colorado School of Medicine; Vaskar Saha, University of Manchester, U.K.; Paul Gaynon, Children's Hospital Los Angeles; Andre Baruchel, Hospital Robert Debre, Paris; Valentino Conter, University of Milan-Bicocca, Italy; Jacques Otten, Brussels University Hospital, Belgium; Akira Ohara, Toho University, Tokyo; Anne Birgitta Versluys, University Medical Center Utrecht, the Netherlands; Gabriele Escherich, University Medical Center Eppendorf, Germany; Mats Heyman, Astrid Lindgren Children's Hospital, Sweden; Lewis Silverman, Dana-Farber Cancer Institute, Boston; Keizo Horibe, Nagoya Medical Center, Japan; Georg Mann, St. Anna Children's Hospital, Vienna; Bruce Camitta, Medical College of Wisconsin, Milwaukee; Jochen Harbott, Justus-Liebig-University, Giessen, Germany; Hansjorg Riehm and Martin Zimmermann, both of Medical School Hannover, Hannover, Germany; Sue Richards, University of Oxford, England; and Meenakshi Devidas, University of Florida, Gainesville.
In the U.S., the work was supported in part by National Cancer Institute grants to the Children's Cancer Group, Pediatric Oncology Group and ALSAC.
St. Jude Children's Research Hospital
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
St. Jude Children's Research Hospital. "For Some Leukemia Patients Who Fail Induction Therapy, Chemotherapy Proves Life-Saving." Medical News Today. MediLexicon, Intl., 12 Apr. 2012. Web.
28 Apr. 2017. <http://www.medicalnewstoday.com/releases/244028.php>
St. Jude Children's Research Hospital. (2012, April 12). "For Some Leukemia Patients Who Fail Induction Therapy, Chemotherapy Proves Life-Saving." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.